MapLight's ML-007C-MA Meets Primary Endpoint in Phase 2 Schizophrenia Trial and Shows Cognitive Gains
MPLT sits 36% above its 52-week low of $12.24.
Summary
MapLight Therapeutics announced positive Phase 2 ZEPHYR trial results for ML-007C-MA in schizophrenia. The study met its primary endpoint and showed a significant cognitive benefit, with the drug proving well-tolerated. The company plans to advance to a confirmatory pivotal trial following an FDA meeting.
Key Events · Product Development and Regulatory · MPLT
-
Primary Endpoint Met
ML-007C-MA 210/3 mg BID achieved a statistically significant reduction in PANSS total score versus placebo at Week 5 (ES=0.37, -4.5 points, p=0.015).
-
Cognitive Benefit Demonstrated
A prespecified secondary endpoint showed significant cognitive improvement (ES=0.51, p=0.041) independent of antipsychotic effect, a potentially differentiating feature.
-
Favorable Safety Profile
No serious or drug-related severe adverse events were observed; GI-related discontinuation was low (2%); and there were no metabolic, hepatic, or movement-related signals, with no fasting requirement or complex titration needed.
-
Regulatory Path Forward
The company plans an End-of-Phase 2 meeting with the FDA and has begun planning a confirmatory pivotal trial to support an NDA submission.
Analysis · MPLT · Life Sciences
The ZEPHYR trial delivered on its primary endpoint with a statistically significant reduction in PANSS total score (ES=0.37, p=0.015) and, notably, a robust cognitive improvement (ES=0.51) on a prespecified secondary endpoint — a potentially differentiating feature in schizophrenia. The drug was well-tolerated, with no serious drug-related adverse events, positioning it favorably against existing therapies. These results de-risk the ML-007C-MA program and support advancement into a confirmatory pivotal trial, with an EOP2 meeting planned with the FDA. The cognitive signal also strengthens the rationale for the ongoing VISTA trial in Alzheimer's disease psychosis, where topline data are expected in 2H 2027.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MPLT was trading at $16.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $12.24 to $40.43. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.